Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis for Non-AMD CNV and AMD-PEDs
NCT01628354Phase 4Completed
- Sponsor
- University of Melbourne
- Start
- Feb 2008
- Primary completion
- Apr 2010
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in choroidal neovascularization (CNV), retinal pigment epithelial detachment (PED), sponsored by University of Melbourne. Started Feb 2008; status: completed.
02
Drugs
ranibizumab
03
Conditions
choroidal neovascularization (CNV)retinal pigment epithelial detachment (PED)
Beyond the preview
Go deeper on NCT01628354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01628354.